Astellas Pharma Gross Profit 2012-2019 | ALPMY

Astellas Pharma annual/quarterly gross profit history and growth rate from 2012 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Astellas Pharma gross profit for the quarter ending December 31, 2019 was $M, a 100% decline year-over-year.
  • Astellas Pharma gross profit for the twelve months ending December 31, 2019 was $6.965B, a 24.06% decline year-over-year.
  • Astellas Pharma annual gross profit for 2020 was $9.422B, a 3.11% increase from 2019.
  • Astellas Pharma annual gross profit for 2019 was $9.138B, a 3.72% decline from 2018.
  • Astellas Pharma annual gross profit for 2018 was $9.491B, a 7.26% increase from 2017.
Astellas Pharma Annual Gross Profit
(Millions of US $)
2020 $9,422
2019 $9,138
2018 $9,491
2017 $8,849
2016 $8,608
2015 $8,318
2014 $7,857
2013 $7,250
2012 $7,936
2011 $11,791
2010 $10,519
2009 $9,947
2008 $9,395
2007 $7,650
2006 $7,993
Astellas Pharma Quarterly Gross Profit
(Millions of US $)
2019-12-31
2019-06-30 $2,399
2018-06-30 $2,377
2017-06-30 $2,190
2016-09-30 $2,344
2016-06-30 $2,476
2016-03-31 $2,088
2015-12-31 $2,264
2015-09-30 $2,177
2015-06-30 $2,079
2015-03-31 $1,825
2014-12-31 $2,270
2014-09-30 $2,076
2014-06-30 $2,148
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $1,911
2013-03-31
2012-12-31
2012-09-30
2012-06-30 $2,122
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $30.738B $11.967B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.380B 37.10
Takeda Pharmaceutical (TAK) Japan $56.087B 9.83
Eisai (ESALY) Japan $23.358B 20.25
UCB SA (UCBJF) Belgium $22.796B 0.00
Merck (MKGAF) Germany $15.419B 20.22
Grifols, S.A (GRFS) Spain $12.857B 15.98
Neurocrine Biosciences (NBIX) United States $11.643B 53.81
Catalent (CTLT) United States $11.267B 43.56
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 0.00
Ionis Pharmaceuticals (IONS) United States $8.469B 45.03
IPSEN SA ADR (IPSEY) France $7.049B 0.00
Orion OYJ (ORINY) Finland $6.766B 30.32
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.664B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.074B 9.72
United Therapeutics (UTHR) United States $5.296B 10.04
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $4.498B 491.11
Nektar Therapeutics (NKTR) United States $4.186B 0.00
Evotec AG (EVTCY) Germany $4.100B 110.61
FibroGen (FGEN) United States $3.876B 0.00
Hypermarcas (HYPMY) Brazil $3.819B 11.62
ChemoCentryx (CCXI) United States $3.588B 0.00
PTC Therapeutics (PTCT) United States $3.470B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.581B 10.60
Sage Therapeutics (SAGE) United States $2.233B 0.00
Pacira BioSciences (PCRX) United States $2.206B 45.15
Cronos Group (CRON) Canada $2.152B 61.70
Corcept Therapeutics (CORT) United States $1.969B 19.52
Xencor (XNCR) United States $1.871B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.752B 0.00
USANA Health Sciences (USNA) United States $1.729B 17.74
Akebia Therapeutics (AKBA) United States $1.704B 0.00
Indivior (INVVY) United States $1.679B 20.84
Ironwood Pharmaceuticals (IRWD) United States $1.622B 12.41
Zogenix (ZGNX) United States $1.615B 0.00
Karyopharm Therapeutics (KPTI) United States $1.441B 0.00
Portola Pharmaceuticals (PTLA) United States $1.415B 0.00
Heron Therapeutics (HRTX) United States $1.408B 0.00
Esperion Therapeutics (ESPR) United States $1.407B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.353B 14.58
Theravance Biopharma (TBPH) Cayman Islands $1.295B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.250B 0.00
Translate Bio (TBIO) United States $1.124B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.999B 44.59
BioCryst Pharmaceuticals (BCRX) United States $0.886B 0.00
Tilray (TLRY) Canada $0.869B 0.00
ImmunoGen (IMGN) United States $0.851B 0.00
Endo (ENDP) Ireland $0.802B 1.24
Radius Health (RDUS) United States $0.657B 0.00
Trillium Therapeutics (TRIL) Canada $0.657B 0.00
Aerie Pharmaceuticals (AERI) United States $0.649B 0.00
Ardelyx (ARDX) United States $0.624B 0.00
Molecular Templates (MTEM) United States $0.618B 0.00
Collegium Pharmaceutical (COLL) United States $0.600B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.576B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.556B 0.00
VAXART, INC (VXRT) United States $0.547B 0.00
Flexion Therapeutics (FLXN) United States $0.511B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.497B 12.02
Siga Technologies (SIGA) United States $0.484B 0.00
Innate Pharma SA (IPHYF) France $0.476B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.458B 17.89
DURECT (DRRX) United States $0.439B 0.00
Ocular Therapeutix (OCUL) United States $0.426B 0.00
Harpoon Therapeutics (HARP) United States $0.415B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.399B 0.00
Organogenesis Holdings (ORGO) United States $0.395B 0.00
TherapeuticsMD (TXMD) United States $0.378B 0.00
MEI Pharma (MEIP) United States $0.370B 0.00
Calithera Biosciences (CALA) United States $0.363B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.322B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.298B 0.00
OptiNose (OPTN) United States $0.296B 0.00
Lannett Co Inc (LCI) United States $0.287B 6.30
PROFOUND MEDICL (PROF) Canada $0.281B 0.00
Concert Pharmaceuticals (CNCE) United States $0.275B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.250B 0.00
CASI Pharmaceuticals (CASI) United States $0.245B 0.00
Redhill Biopharma (RDHL) Israel $0.239B 0.00
KalVista Pharmaceuticals (KALV) United States $0.231B 0.00
Jounce Therapeutics (JNCE) United States $0.222B 5.29
Rafael Holdings (RFL) United States $0.222B 0.00
Taiwan Liposome (TLC) Taiwan $0.215B 0.00
Nivalis Therapeutics (ALPN) United States $0.189B 0.00
Nature's Sunshine Products (NATR) United States $0.177B 23.33
IMV INC (IMV) Canada $0.176B 0.00
Altimmune (ALT) United States $0.162B 0.00
Aquestive Therapeutics (AQST) United States $0.158B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.152B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.147B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.120B 0.00
Champions Oncology (CSBR) United States $0.117B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.110B 0.00
Recro Pharma (REPH) United States $0.108B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.106B 0.00
Xeris Pharmaceuticals (XERS) United States $0.105B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.102B 0.00
Onconova Therapeutics (ONTX) United States $0.098B 0.00
Otonomy (OTIC) United States $0.098B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.096B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.095B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.092B 0.00
MediWound (MDWD) Israel $0.092B 0.00
CTI BioPharma (CTIC) United States $0.087B 0.00
Sundial Growers (SNDL) Canada $0.084B 0.00
Biomerica (BMRA) United States $0.083B 0.00
Hemispherx BioPharma (AIM) United States $0.079B 0.00
Heat Biologics (HTBX) United States $0.074B 0.00
SCYNEXIS (SCYX) United States $0.071B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.067B 0.00
Aclaris Therapeutics (ACRS) United States $0.063B 0.00
Lipocine (LPCN) United States $0.063B 0.00
CV Sciences (CVSI) United States $0.060B 0.00
RENEURON GP (RNUGF) United Kingdom $0.057B 0.00
Addex Therapeutics (ADXN) Switzerland $0.052B 0.00
Infinity Pharmaceuticals (INFI) United States $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.049B 29.45
PolarityTE (PTE) United States $0.048B 0.00
Natural Alternatives (NAII) United States $0.047B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.043B 0.00
GTx (ONCT) United States $0.042B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.042B 0.00
Forward Pharma (FWP) Denmark $0.042B 0.00
Mannatechorporated (MTEX) United States $0.041B 7.71
Adamis Pharmaceuticals (ADMP) United States $0.040B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.039B 83.00
Novan (NOVN) United States $0.039B 0.00
IsoRay (ISR) United States $0.038B 0.00
Neos Therapeutics (NEOS) United States $0.034B 0.00
AgeX Therapeutics (AGE) United States $0.033B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.031B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.028B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
India Globalization Capital (IGC) United States $0.022B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
Iterum Therapeutics (ITRM) Ireland $0.021B 0.00
Flex Pharma (SLRX) United States $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.018B 0.00
Can-Fite Biopharma (CANF) Israel $0.017B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
China SXT Pharmaceuticals (SXTC) China $0.015B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Shineco (TYHT) China $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 33.86
Sonoma Pharmaceuticals (SNOA) United States $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.010B 0.00
Vical (BBI) United States $0.010B 0.00
Midatech Pharma (MTP) United Kingdom $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.009B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00